Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prolgolimab in relapsed/refractory classical Hodgkin lymphoma
NCT05757466Phase 2Recruiting
- Sponsor
- First Saint Petersburg State Medical University
- Start
- Apr 2023
- Primary completion
- Mar 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of prolgolimab in classical Hodgkin lymphoma (cHL), sponsored by First Saint Petersburg State Medical University. Started Apr 2023; status: recruiting.
02
Drugs
prolgolimab
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT05757466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05757466.